Geoffrey K Herkes
Overview
Explore the profile of Geoffrey K Herkes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
328
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smith J, Menzies A, Cohen J, Mut-Lloret M, Ozgun A, Spain L, et al.
Melanoma Res
. 2022 Sep;
32(6):451-459.
PMID: 36164923
Anti-programmed cell death protein 1 (PD1) antibodies, pembrolizumab and nivolumab, alone or in combination with ipilimumab, have become standard treatment for melanoma and multiple other malignancies. Neurological adverse effects are...
2.
Rapport F, Hutchinson K, Herkes G, Bleasel A, Nikpour A, Ryder T, et al.
BMJ Open
. 2021 Jan;
11(1):e043553.
PMID: 33495260
Introduction: Epilepsy is a common neurological condition affecting between 3% and 3.5% of the Australian population at some point in their lifetime. The effective management of chronic and complex conditions...
3.
Barnes S, Herkes G
Intern Med J
. 2019 Nov;
50(12):1500-1504.
PMID: 31760675
Background: Guillain-Barré syndrome (GBS) causes acute neuromuscular weakness. Severe cases are life-threatening and many are left disabled. Intravenous immunoglobulin (IVIg) and plasma exchange (PE), along with supportive care, are the...
4.
Stockings E, Zagic D, Campbell G, Weier M, Hall W, Nielsen S, et al.
J Neurol Neurosurg Psychiatry
. 2018 Mar;
89(7):741-753.
PMID: 29511052
Prospero Registration Number: CRD42017055412.
5.
Cadilhac D, Kilkenny M, Levi C, Lannin N, Thrift A, Kim J, et al.
Med J Aust
. 2017 Apr;
206(8):345-350.
PMID: 28446116
Objectives: Hospital data used to assess regional variability in disease management and outcomes, including mortality, lack information on disease severity. We describe variance between hospitals in 30-day risk-adjusted mortality rates...
6.
McGrath R, Hocking S, Priglinger M, Day S, Herkes G, Krause M, et al.
BMJ Open
. 2016 Feb;
6(2):e008203.
PMID: 26911582
Introduction: Both hyperglycaemia and hypoglycaemia in acute ischaemic stroke (AIS) are associated with increased infarct size and worse functional outcomes. Thus, therapies that can maintain normoglycaemia during stroke are clinically...
7.
Hardy T, OBrien B, Gerbis N, Barnett M, Reddel S, Brewer J, et al.
J Neurol Neurosurg Psychiatry
. 2014 Aug;
86(5):582-4.
PMID: 25168394
No abstract available.
8.
Geevasinga N, Cole C, Herkes G, Barnett Y, Lin J, Needham M
J Clin Neurosci
. 2014 Mar;
21(8):1329-32.
PMID: 24656986
Sickle cell disease can present with neurological manifestations. One such presentation is with posterior reversible leukoencephalopathy also known as reversible posterior leukoencephalopathy. The condition is classically described as reversible over...
9.
Blair N, Orr C, Delaney A, Herkes G
Med J Aust
. 2013 May;
198(8):440-2.
PMID: 23641996
No abstract available.
10.
Chui J, Herkes G, Chang A
JAMA Ophthalmol
. 2013 Mar;
131(5):694-6.
PMID: 23538612
No abstract available.